The Food and Drug Administration approved the monoclonal antibody treatment Beyfortus to prevent respiratory syncytial virus—the leading cause of hospitalizations in U.S. infants less than a year old.
The drug—made by AstraZeneca—will be administered as a single injection to infants prior to RSV season in the latter months of the year. Around 2% of children less than a year old are hospitalized by RSV every year, according to the American Academy of Pediatrics.
This is a developing story. Check back for updates.